Evolus Inc (NASDAQ:EOLS) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 996,612 shares, a decline of 41.9% from the July 13th total of 1,714,462 shares. Based on an average trading volume of 705,922 shares, the days-to-cover ratio is currently 1.4 days. Approximately 11.3% of the company’s shares are sold short.
In related news, Director Vikram Malik acquired 8,600 shares of the business’s stock in a transaction that occurred on Thursday, June 14th. The shares were bought at an average cost of $28.88 per share, with a total value of $248,368.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Corp Alphaeon sold 1,000,000 shares of Evolus stock in a transaction that occurred on Monday, July 23rd. The stock was sold at an average price of $18.80, for a total value of $18,800,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 27,840 shares of company stock worth $797,007.
Hedge funds have recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in Evolus in the second quarter worth approximately $108,000. Tower Research Capital LLC TRC increased its holdings in Evolus by 761.4% in the second quarter. Tower Research Capital LLC TRC now owns 6,555 shares of the company’s stock worth $183,000 after purchasing an additional 5,794 shares in the last quarter. Mizuho Securities USA LLC bought a new stake in Evolus in the first quarter worth approximately $226,000. Schwab Charles Investment Management Inc. bought a new stake in Evolus in the second quarter worth approximately $258,000. Finally, Alpine Woods Capital Investors LLC bought a new stake in Evolus in the second quarter worth approximately $280,000. Institutional investors and hedge funds own 16.60% of the company’s stock.
Evolus (NASDAQ:EOLS) last issued its earnings results on Thursday, August 2nd. The company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.05). equities analysts anticipate that Evolus will post -1.9 EPS for the current year.
A number of equities analysts recently commented on the company. JMP Securities lifted their price objective on Evolus from $22.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 29th. ValuEngine raised Evolus from a “hold” rating to a “buy” rating in a research note on Monday, July 2nd. Cantor Fitzgerald set a $35.00 price objective on Evolus and gave the stock a “buy” rating in a research note on Monday, July 23rd. Zacks Investment Research lowered Evolus from a “buy” rating to a “hold” rating in a research note on Thursday, August 2nd. Finally, Mizuho reaffirmed a “buy” rating on shares of Evolus in a research note on Wednesday, May 16th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $30.40.
Evolus Company Profile
Evolus, Inc provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.
Recommended Story: Investing in Growth Stocks
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.